You just read:

Phase 3 COLUMBA Study Investigating a Subcutaneous Formulation of DARZALEX® (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Jun 02, 2019, 10:45 ET